

# Patient-centred nurse-led clinic for patients with liver cirrhosis

<b>Submission date</b> 31/01/2023	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 10/02/2023	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 07/10/2024	<b>Condition category</b> Digestive System	<input type="checkbox"/> Individual participant data <input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Cirrhosis is scarring of the liver caused by continuous, long-term liver damage. The rate of death from liver cirrhosis is high. The risk of death depends on how the complications are treated and prevented. The only treatment for advanced liver cirrhosis is liver transplantation. To be eligible for transplantation, the patient will have to meet a number of criteria. Furthermore, there needs to be an organ available for the patient. Organs for transplant are limited. Consequently, only a minority of patients with advanced liver cirrhosis are transplanted. Focus is therefore to minimize, avoid or remove factors that can lead to complications. Initiatives to do so could include lifestyle changes, increased self-care and increased adherence. Subgroups of patients with liver cirrhosis have low levels of health literacy and may therefore need patient-tailored information and guidance. One-third of episodes with complications are found to be preventable with closer follow-up in an outpatient setting. The aim of this study is to establish a nurse-led clinic for patients with liver cirrhosis in order to reduce acute admissions.

### Who can participate?

The study will include adult patients with decompensated liver cirrhosis followed at Aarhus University Hospital, Denmark. Decompensated liver cirrhosis is characterised by one or more of the following complications: ascites, variceal bleeding or hepatic encephalopathy. Eligible patients will need close contact with the hospital in order to prevent acute admissions.

### What does the study involve?

The intervention will be individual contact with liver-nurses in the clinic. The contact will be individual and can include telephone contacts, physical appointments and/or communication with relatives or caregivers. Patients will only be followed until they have a good understanding of their condition, are well-regulated on medical treatment, and have a high level of self-care.

A cohort of approximately 800 patients that have the diagnosis of liver cirrhosis will be the main data source in the study. The study will run for 2-3 years (2022-2025). Key parameters for acute admission will continuously be monitored prior to, during and after the study. The effect will be calculated using acute admission data from all patients in the period mentioned above.

What are the possible benefits and risks of participating?

Participants will hopefully achieve better understanding of their disease, symptoms and ways to self-care. Furthermore, the participants will have a closer personal contact to the hospital and acute admissions will be reduced. The potential risk of participating is close to zero.

Where is the study run from?

The study will run from Aarhus University Hospital, Denmark.

When is the study starting and how long is it expected to run for?

August 2019 to September 2024

Who is funding the study?

The study is funded by donations from Central Denmark Region, Aarhus University Hospital and The Novo Nordisk Foundation.

Who is the main contact?

Senior researcher, associated professor Palle Bager, pallbage@rm.dk

## Contact information

### Type(s)

Principal Investigator

### Contact name

Dr Palle Bager

### ORCID ID

<http://orcid.org/0000-0002-9871-9624>

### Contact details

Department of Hepatology and Gastroenterology  
Aarhus University Hospital  
Palle Juul-Jensens Boulevard 99  
Århus N  
Denmark  
8200  
+45 51500697  
[palle.bager@aarhus.rm.dk](mailto:palle.bager@aarhus.rm.dk)

## Additional identifiers

### EudraCT/CTIS number

Nil known

### IRAS number

### ClinicalTrials.gov number

Nil known

### Secondary identifying numbers

## Study information

### Scientific Title

Patient-centred nurse-led clinic for patients with liver cirrhosis, aiming to improve the clinical course of the condition. A quasi-experimental longitudinal study with a dynamic cohort

### Study objectives

After full implementation of a patient-centered nurse-led clinic, the number of clinical incidences, leading to admission to hospital- ward or outpatient clinic, will drop by 25% for the whole cohort.

### Ethics approval required

Ethics approval not required

### Ethics approval(s)

The study does not require ethical approval in Denmark. The study does not include medical intervention and no human biological material will be collected.

### Study design

Single-centre quasi-experimental longitudinal study including a dynamic cohort

### Primary study design

Interventional

### Secondary study design

Non randomised study

### Study setting(s)

Hospital

### Study type(s)

Prevention

### Participant information sheet

No participant information sheet available

### Health condition(s) or problem(s) studied

Preventing acute admissions for patients with decompensated liver cirrhosis

### Interventions

The key intervention will be to establish a patient-centred nurse-led clinic.

The clinic will offer patients individual talks about their disease and the related problems. Using the tool motivational interviewing, the nurse will identify the most important issues for each patient. Based on the shared decision-making, customized and comprehensive care plans for each patient will be developed. Furthermore, the nurses will have delegated authorisation to adjust selected medical treatment.

As the aim is to prevent acute admission to hospital. Consequently, the intervention will be individual, - in content, in frequency, and in duration.

Eligible patients will be recruited from the hospital ward or the outpatient clinic.

The patients will be screened for possible health-related problems (e.g. ascites, nutrition, compliance, medical treatment, alcohol abuse) and possible accompanying problems (e.g. housing, weak social network, transport, economic).

Based on screening, an individual intervention will be planned and executed. This could include physical appointment, education of the patient (and relatives), telephone calls, contact to the primary health care etc.

The intervention will end (and the patient will stop in the trial) when the patient is well informed and well established with the condition of liver cirrhosis and able to perform self-care. The intervention will also end if the patient turns out to be non-compliant or obviously not able to benefit from the intervention; - or if the patient dies.

Data on patient contact and the nature of intervention will continuously be collected.

Furthermore, the overall hospital-related activity for the total cohort of patients with liver cirrhosis (approximately 800 patients) will be monitored on a monthly basis (interrupted time series) aiming (at the end of the trial) to be able to describe the effect of the intervention as changes in acute activity.

## **Intervention Type**

Behavioural

## **Primary outcome measure**

Acute admissions to hospital- ward or outpatient clinic by 25% for the whole cohort at the end of trial compared to data prior to the intervention.

Data on acute admissions and specific procedures linked to the admission have continuously been recorded in a hospital database since 2019. The primary measurement will be data from this source in order to detect changes (on cohort level) after the implementation of the clinic. The individual patient will add data to this database, regardless of participation in the trial or not. The total cohort will be regarded as dynamic, as some patients will leave the cohort (die or move) and new patients will enter the cohort. Calculation will be performed on the whole cohort (approximately 800 patients) and per 100 patients.

## **Secondary outcome measures**

1. Every trial activity for the patients included will be recorded at each trial activity. This includes type of activity and content. These data combined with data described under primary outcome measures, will be used for health economic analysis (budget impact analysis) at the end of trial.
2. Feasibility of establishing a nurse-led clinic will be measured by qualitative methods.

## **Overall study start date**

01/08/2019

## **Completion date**

30/09/2024

# **Eligibility**

## **Key inclusion criteria**

1. Eligible patients will be adult patients with decompensated liver cirrhosis who are estimated to be able to benefit from the intervention.
2. Patients who need information, coordination and close contact with the hospital in order to prevent acute admissions.

**Participant type(s)**

Patient

**Age group**

Mixed

**Lower age limit**

18 Years

**Upper age limit**

130 Years

**Sex**

Both

**Target number of participants**

80

**Total final enrolment**

55

**Key exclusion criteria**

1. Patients who are well informed and/or have a well-functioning network.
2. Patients who are predominantly non-compliant and/or not receptive to information and care.

**Date of first enrolment**

01/01/2022

**Date of final enrolment**

30/06/2024

**Locations****Countries of recruitment**

Denmark

**Study participating centre**

**Aarhus University Hospital**

Department of Hepatology and Gastroenterology

Palle Juul-Jensens Boulevard 99

Aarhus N

Denmark

8200

**Sponsor information**

**Organisation**

Aarhus University Hospital

**Sponsor details**

Palle Juul-Jensens Boulevard 99

Aarhus N

Denmark

8200

+45 784500

auhhov@rm.dk

**Sponsor type**

Industry

**Website**

<http://www.en.auh.dk/>

**ROR**

<https://ror.org/040r8fr65>

**Funder(s)****Funder type**

Government

**Funder Name**

Region Midtjylland

**Alternative Name(s)**

Central Denmark Region, RM

**Funding Body Type**

Government organisation

**Funding Body Subtype**

Local government

**Location**

Denmark

**Funder Name**

Aarhus Universitetshospital

**Alternative Name(s)**

Aarhus University Hospital, AUH

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

Other non-profit organizations

**Location**

Denmark

**Funder Name**

Novo Nordisk Pharma

**Alternative Name(s)**

Novo Nordisk Japan, Novo Nordisk Pharma Ltd

**Funding Body Type**

Private sector organisation

**Funding Body Subtype**

For-profit companies (industry)

**Location**

Japan

## Results and Publications

**Publication and dissemination plan**

Planned publication in a high-impact peer-reviewed journal.

**Intention to publish date**

02/01/2025

**Individual participant data (IPD) sharing plan**

The data-sharing plans for the current study are unknown and will be made available at a later date

**IPD sharing plan summary**

Data sharing statement to be made available at a later date